CD16/CD32 mAb (2.4G2), InVivoPure+

InVivo Biotech

CD16/CD32 mAb (2.4G2), InVivoPure+

5

Neutralisation/Blocking

Research Use Only

Monoclonal

2.4G2

1 mg/ml

Unconjugated

>=95%

Liquid

Fcgr2b

Fc receptor, IgG, low affinity IIb

AI528646; CD32; F630109E10Rik; fc gamma receptor IIB; Fc gamma RIIB; Fc[g]; Fc[g]RII; Fcg; Fcgamm; fc-gamma RII; Fc-gamma-RII; FcgammaRIIB; fc-gamma-RIIB; Fcgr; Fcgr2; Fcgr2a; FcgRII; Fcr-; Fcr-2; Fcr-3; fcRII; igG Fc receptor II beta; low affinity immunoglobulin gamma Fc region receptor II; low affinity immunoglobulin gamma Fc region receptor II-b; Ly-1; Ly-17; LyM-; LyM-1; Ly-m2; Ly-m20; lymphocyte antigen 17

Mouse

IgG2b

Low affinity immunoglobulin gamma Fc region receptor II

CD16/CD32 (2.4G2) rat antibody recognizes endogenous levels of total CD16/CD32 protein. This antibody detects an epitope within the extracellular domain and is expected to detect all isoforms of CD16 and CD32. 2.4G2 antibody blocks the interaction between IgG and CD16 or CD32, and therefore is used as a pre-treatment to minimize non-specific binding of antibodies to FcR-bearing cells. CD16/CD32 is expressed on NK cells, monocytes, macrophages, dendritic C (at low levels) kupper cells, granulocytes, mast cells, B lymphocytesand some activated T lymphocyte

Mouse

12352203